Related Experiment Video
Updated: Dec 11, 2025

Lipidomics and Transcriptomics in Neurological Diseases
Published on: March 18, 2022
Exploration of Plasma Lipids in Mild Cognitive Impairment due to Alzheimer's Disease
Anne Katrine Bergland1,2, Petroula Proitsi3, Bjørn-Eivind Kirsebom4,5
1Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway.
Background:
Lipids have important structural roles in cell membranes and changes to these membrane lipids may influence β- and γ-secretase activities and thus contribute to Alzheimer's disease (AD) pathology.
Objective:
To explore baseline plasma lipid profiling in participants with mild cognitive impairment (MCI) with and without AD pathology.
Methods:
We identified 261 plasma lipids using reversed-phase liquid chromatography/mass spectrometry in cerebrospinal fluid amyloid positive (Aβ+) or negative (Aβ-) participants with MCI as compared to controls. Additionally, we analyzed the potential associations of plasma lipid profiles with performance on neuropsychological tests at baseline and after two years.
Results:
Sphingomyelin (SM) concentrations, particularly, SM(d43:2), were lower in MCI Aβ+ individuals compared to controls. Further, SM(d43:2) was also nominally reduced in MCI Aβ+ individuals compared to MCI Aβ-. No plasma lipids were associated with performance on primary neuropsychological tests at baseline or between the two time points after correction for multiple testing.
Conclusion:
Reduced plasma concentrations of SM were associated with AD.
More Related Videos
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease: Treatment
Dementia
The progression of dementia is generally gradual....
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

